Home - Australian Pharmacist

Minimising harm, building trust

Brian Bigg - May 25, 2020

Industry

Australian Pharmacist of the Year 2017 Irvine Newton OAM FPS was inaugural chairman of PSA’s Harm Minimisation Committee in Victoria.

Top tips for pharmacists as COVID-19 immunisation ramps up

Ruth Cooper - June 9, 2021

Queensland pharmacist Matthew Hoy MPS has been administering COVID-19 vaccinations since March.

Industry

Community pharmacists delivered their first COVID-19 vaccinations in Queensland this week, and more are expected to come online soon in other states.

Experts recommend 10 ways to prevent medicine-related harm

Ruth Cooper - June 30, 2021

A group of Australia’s leading medicine safety experts is calling for action to reduce medicine-related harms.

Industry

A group of Australia’s leading medicine safety experts is calling for action to reduce avoidable deaths, hospitalisations and quality-of-life impacts caused by unsafe medicine use.

Starting in FIP as an ECP was the best

Jennifer Cooke - September 22, 2023

People

Professor Rebekah Moles FPS also juggles academia, family and plays her Flea edition pink Fender bass guitar in two fun bands.

The extent of drug-related problems in HMRs

Dr Lisa Kouladjian O'Donnell MPS & Susan Edwards FPS - May 29, 2019

Clinical

Research highlights the vital role HMRs play in averting medicine misadventure. In 2016, members of the PSA Accredited Pharmacist Leadership Group (APLG) undertook an...

Pharmacist remuneration to increase

Dr Chris Freeman FPS - June 19, 2019

Industry

PSA has been working to address one of the key issues raised by its members – remuneration – and is pleased to see the...

1...186187188...318 Page 187 of 318

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

ACT³	No comparable criteria
NSW⁴	· pharmacist gives the person an opportunity to seek advice as to the use of the substance · quantity, or for a purpose must accord with the recognised therapeutic standard of what is appropriate in the circumstances
NT⁵	· pharmacist must not intentionally supply to a person in a manner reckless to their circumstance
QLD⁶	· pharmacist reasonably believes the patient has a therapeutic need
SA	No comparable criteria
TAS⁷	· pharmacist forms the opinion use in the treatment of the patient is justified on consideration of the condition, disease or symptoms of the person
VIC⁸	· for treatment of a patient under pharmacist’s care · pharmacist has taken all reasonable steps to ensure a therapeutic need exists
WA⁹	No comparable criteria

Case scenario

Learning objectives

Introduction

Epidemiology

Aetiology and pathophysiology

Risk factors

Clinical features

Management

Knowledge to practice

Case scenario continued

Key points

References

Our author

Our reviewer

1. Therapeutic Guidelines overhaul UTI treatment

2. Is Rikodeine still being rescheduled?

What else was popular?

1. PBS co‑payment will drop

2. Transition to the new MMR credential must be completed

3. Continued freeze on PBS concessional co‑payment

4. Optional allowable discount phase out continues

5. New PSA standards for CPD accreditation launch

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

Case scenario

Learning objectives

Introduction

Epidemiology

Aetiology and pathophysiology

Risk factors

Clinical features

Management

Knowledge to practice

Case scenario continued

Key points

References

Our author

Our reviewer

1. Therapeutic Guidelines overhaul UTI treatment

2. Is Rikodeine still being rescheduled?

What else was popular?

1. PBS co‑payment will drop

2. Transition to the new MMR credential must be completed

3. Continued freeze on PBS concessional co‑payment

4. Optional allowable discount phase out continues

5. New PSA standards for CPD accreditation launch

Is advance provision of S3s legal?

But don’t we need to assess a patient’s therapeutic need?

So when is advanced supply of S3 OK?

What other things do I need to consider?

So what about the Rikodeine?

Table 1 – Legal requirements for pharmacists when prescribing Schedule 3 medicines

References

Case scenario

Learning objectives

Introduction

Epidemiology

Aetiology and pathophysiology

Risk factors

Clinical features

Management

Knowledge to practice

Case scenario continued

Key points

References

Our author

Our reviewer

1. Therapeutic Guidelines overhaul UTI treatment

2. Is Rikodeine still being rescheduled?

What else was popular?

1. PBS co‑payment will drop

2. Transition to the new MMR credential must be completed

3. Continued freeze on PBS concessional co‑payment

4. Optional allowable discount phase out continues

5. New PSA standards for CPD accreditation launch